Eli Lilly is a strong candidate for healthcare stock investment, actively expanding its drug pipeline, particularly in weight loss and cancer therapies, with significant recent acquisitions. The company's robust growth, evidenced by a 43% revenue increase year-over-year, positions it well in a healthcare sector projected to grow as the population ages.
Consider adding Eli Lilly (NYSE: LLY) to your portfolio as it is a leader in the weight-loss drug market and is expanding its pipeline through strategic acquisitions, such as the $7 billion purchase of Kelonia Therapeutics. With a forward P/E ratio of 40, below its five-year average, and a significant increase in revenue and EPS, Eli Lilly presents a potentially undervalued opportunity for growth in the healthcare sector.